These data reveal that the LCN2–JAK2–STAT3 axis is a crucial regulator of VEGF-A-driven angiogenesis, suggesting that the LCN2–JAK2–STAT3 axis is a promising therapeutic target for lung cancer patients with BM characterized by high LCN2 expression. This evidence concerns the gene LCN2 and lung cancer.